

Pharmacy and Therapeutics Committee Meeting
June 3rd, 2003
Kellogg Hotel and Conference Center

Draft Minutes

Committee Members in Attendance:

David Johnson, M.D., Chairman
Giovanini Perri, M.D.
Robert Coffey, Pharm.D.
Debra Eggleston, M.D.
Jonathon Henry, M.D.
Edward Keating, R.Ph.
Max Robins, D.O.

Not in Attendance:

Sandra Campbell, Pharm.D.
Robert Ernst, M.D.

State of Michigan Representatives in Attendance:

Doris R. Gellert, Director, Pharmacy, Medical and Beneficiary Services Bureau
George Baker, M.D., Office of Medical Affairs
Brad Sprecher, Pharmacy, Medical and Beneficiary Services Bureau

First Health Services Corporation Representatives in Attendance:

Annette Paul, Medicaid Clinical Manager
Bruce Edgren, Sr. Director Clinical Program Development

Audience:

Approximately 70 members of the public, including physicians and drug company representatives, were in attendance.

- I. The meeting is called to order at 6:15 p.m. by Dr. David Johnson
- II. Dr. Johnson moderates the public comments, from the following constituencies (in the order of presentation):

Wyeth: Dr. Ronald Melvin
Astra Zeneca: Dr. Peter Jochimsen
Glaxo Smith Klein: Todd Edwards

Alex Masterson: presents Strattera research on behalf of Eli Lilly
 Eli Lilly: Dr. Mahalakshmi Honasoge (Forteo)
 Hoffmann-LaRoche: Archie Shew and Dr.Phil Spagnuolo
 Karen Meyerson: asthma advocacy (PAANWM)
 Schering-Plough: Dr. Pinakin Attawalla
 Organon Pharmaceuticals: Dr Carolyn Jones

- III. Dr. Johnson calls for approval of the minutes from the April 14th P&T and May 13th P&T meetings.

The minutes are approved without modification.

- IV. Annette Paul, First Health Services Corporation, provides a review of new drug products for coverage considerations.

The Committee makes the following coverage recommendations for these recently released products:

Drug	PDL Class	PDL Preferred Drug?	Clinical PA Required?	Committee member Comments
Fuzeon	No (HIV-AIDS)	No	No	The Committee recommends coverage of Fuzeon without prior authorization. Utilization to be reviewed at 6 months.
Somavert	No (acromegaly)	No	No	The Committee recommends coverage of Somavert without prior authorization.
Emend	The committee voted (06/03/03) to approve "anti-emetics" as a new PDL category.	No	Yes	The Committee recommends Emend not receive preferred status on the Michigan PDL . It is noted that the safety profile has not been established for pediatrics. The pediatric consideration should become part of the PA criteria language.

Drug	PDL Class	PDL Preferred Drug?	Clinical PA Required?	Committee member Comments
Iressa	No (anti-neoplastic)	No	No	The Committee recommends coverage of Iressa with age edit for pediatrics due to the lack of safety information. Iressa is otherwise not a first-line agent. Utilization to be reviewed at 6 months.
Forteo	Yes. The committee voted (06/03/03) to divide the osteoporosis agents into 2 PDL categories: one including Evista and Forteo, the second including Miacalcin, et al.	No	Yes	The Committee recommends prior authorization of Forteo.
Fabrazyme	No	No	No	The Committee recommends coverage of Fabrazyme without prior authorization.
Strattera	Yes. The Committee voted (06/03/03) to add CNS stimulants as a PDL category.	No	Yes	The Committee recommends that Strattera not be preferred. Coverage will be re-considered/reviewed at the September 9 th P&T meeting.

V. Dr. Perri provides the recommendations of the Psychotropic Work Group.

The Committee makes coverage preference recommendations for the psychiatric/CNS products.

VI. Doris Gellert presents a draft document detailing recommendations for product preferences including all previous P&T coverage preferences, while incorporating cost recommendations from First Health.

The P&T committee reviews and votes upon each recommendation in the draft document. The document is approved with modifications.

VII. The meeting adjourns at 9:25 p.m.

**Next meeting is September 9th, 2003
6:00-9:00 p.m.
Kellogg Hotel and Conference Center**

Respectfully submitted by Bradley S. Sprecher